A small trickle brings bold advances


Our BioChip is developed to tackle difficulties in distinguishing diseases with very similar symptoms and aid front-line professionals with making patient management decisions. This is achieved by targeting multiple diseases through a microarray.

  • Global episodes and deaths attributable to lower respiratory infections in 2016 are around 300 million. Respiratory infections place a significant socioeconomic burden on individuals, families, and society. It causes illnesses that range in severity and sometimes lead to hospitalization and death.

  • With our multiplex BioChip, we provide 5-in-1 respiratory diseases diagnostics for SARS-CoV-2, RSV, Streptococcus, Influenza A and Influenza B
  • Dengue fever is common in more than 100 countries around the world. 40% of the world’s population, about 3 billion people, live in areas with a risk of dengue. A blood test is the only way to confirm the diagnosis.
  • With our ALiA® platform, we provide a one-stop blood test for dengue and similar viruses like Zika or chikungunya within 15 minutes.
  • More than 1 million sexually transmitted infections (STIs) are acquired every day worldwide. WHO estimated 376 million new infections with 1 of 4 STIs: chlamydia (127 million), gonorrhoea (87 million), syphilis (6.3 million), and trichomoniasis (156 million).

  • With ALiA® BioChip, a quick screen of suspected viral infections can be achieved at the point of care scenarios for men and women.
  • Rapid diagnostics of Sepsis play an important role in relieving the burden of over 10 million global cases of blood infection-related death.


  • Respiratory and diarrhea infections are the largest contributors to sepsis cases and sepsis-related mortality across all ages in 2017.


  • With our development of Sepsis panel, we offer a comprehensive diagnostic solution for life-threatening and time-critical infections.
  • Outbreak of gastrointestinal infections (GI) is a serious concern in hospitals. Clostridium difficile infection (CDI) is a major cause of hospital-associated GI illness and creates a huge burden on the healthcare system. With our array-based BioChip, we provide diagnostic tests for CDI and its toxins, which can be further developed into panels distinguishing viral, bacterial, and parasite infections.


  • The ALiA® SARS-CoV-2 Antigen FIA Test employs a unique immunofluorescent-based BioChip with our advanced microfluidic and microarray technologies for the qualitative detection of nucleocapsid protein from SARS-CoV-2.


  • The ALiA® SARS-CoV-2 Antigen FIA Test delivers a 20-minute result of direct nasopharyngeal swab from COVID-19 suspected patients with symptoms onset within 14 days.
  • Benefiting from our well-established Lab-On-Chip (LOC) platform (including the POC device and the Lab-On-Chip BioChip), the multiplexing microarray development for various test panels (e.g. 5-in-1 respiratory virus panel) is scalable with a short period of 6-9 months for new application adaption.


Load sample into BioChip


Put into the tray and enter ID


Print the report

Easy to Use

With ALiA® Platform